withdraw from the study. The primary endpoint is progression-free survival (PFS) as assessed by the investigator in the all-comers population and the dMMR population per RECIST version 1.1. Secondary efficacy endpoints are PFS assessed by blinded independent central review per RECIST version 1.1, overall survival, objective response rate, duration of response, disease control rate, safety and tolerability, and patient-reported outcomes.

Disclosures Sponsor: GlaxoSmithKline, Waltham, MA, USA
NCT number: NCT03981796

Encore statement: This data is presented on behalf of the original authors with their permission. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29–31, 2020, Virtual.

Dr. Mirza reports personal fees and other from Karyopharm Therapeutics; Personal fees and other from Sera Prognostics and Roche; Grants and Personal fees from AstraZeneca, Clovis Oncology, Pfizer, GSK, Genmab, BioCad, Sotio, Boehringer Ingelheim, Geneo Therapeutics, Merck, Oncology Venture, Seattle Genetics, Sera Prognostics, Takeda Pharmaceutical Company Ltd, and Zailab.

Dr. Coleman reports consulting fees from Merck, Roche/Genentech, AstraZeneca, Oncomed/Mateo, Novocure, Oncosec, Janssen, Clovis, Tesaro/GSK, Abbvie, Eisai, Arrivive, and Oncoquest; grants from Merck, Roche/Genentech, V-Foundation, AstraZeneca, Janssen, Clovis, Genmab and Abbvie; and honoraria/reimbursement from Merck, Roche/Genentech, AstraZeneca, Oncomed/Mateo, Novocure, Oncosec, Janssen, Clovis, Tesaro/GSK, Abbvie, Arrivive and OncoQuest.

Dr. Slomovitz reports consulting/advisory fees from GlaxoSmithKline.

Dr. Powell reports consulting/advisory fees from Roche/Genentech, AstraZeneca, Tesaro, and Clovis Oncology; and speakers’ bureau at Genentech/Roche, AstraZeneca, Tesaro and Clovis Oncology.

Drs. Harker and Valabrega have nothing to disclose.

Drs. Im, Walker, and Guo are employees of GlaxoSmithKline.

Methodology Patients (N=540) will have PROC (RECIST V1.1) within 6 months of last platinum therapy with maximum of 2–5 prior lines of systemic therapy, ECOG 0–1 and no peripheral neuropathy >grade1. Patients with primary refractory disease will be excluded. Patients will be randomized 1:1 to weekly paclitaxel alone or weekly paclitaxel (starting of dose 80 mg/m2 weekly for 8 weeks, and then on Days 1, 8, and 15 for subsequent 28-day cycle) plus TTFields (200 kHz for 18 hours/day and continued if no progression in the abdominal or pelvic regions (‘in-field region’) per RECIST V1.1. Clinical follow-up will be performed q4w, with radiological follow-up (CT or MRI scans of the abdomen and chest) q8w. The primary endpoint is overall survival. Secondary endpoints: PFS, objective response rate, AE, and quality of life (EORTC QLQ-C30 with QLQ-OV28). Sample size (n=540) will detect an increase in median OS from 12 to 16 months (HR 0.75). Data Monitoring Committee (DMC) meeting (March 2020) concluded that data to-date showed no safety issues and recommended trial continuation.

Results TiP N/A
Conclusion TiP N/A
Disclosures

554 BIOPSR STUDY: ULTRASOUND-GUIDED PREOPERATIVE BIOPSY TO ASSESS HISTOLOGY OF SARCOMA-SUSPICIOUS UTERINE TUMORS. A NEW STUDY PROTOCOL

1Stamatis Petousis, 2Sabrina Croce, 2Michel Kind, 2Caroline Lalet, 2Guillame Babin, 1Chrysoula Margioulia-Sirakou, 3Dennis Queuleu, 3Anne Floquet, 3Marina Pulido, 2Frederic Guyon, 12nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki; 1Institut Bergonie, Bordeaux, France; 2Institut Bergonie, Bordeaux, France; 2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Greece

10.1136/ijgc-2020-ESGO.199

Topic: Trials in progress abstract

Introduction/Background The preoperative differential diagnosis between a uterine fibroma and a sarcoma is a challenge. Available diagnostic tools are rather inconclusive to distinguish between two pathologies. However, potential accurate diagnostic methods would be of great clinical impact in order to optimize surgical treatment.

Methodology A prospective multi-center interventional study will be performed. Ten tertiary French centers will participate in the present study. The overall inclusion study period will be 2 years, overall study duration will be 5 years. Patients greater than 35 years old, diagnosed with suspicious uterine tumor and needing surgical intervention will be included. Uterine tumors will be considered as suspicious in case of rapid tumor growth (>30% of the maximum diameter in 1-year interval), symptomatic tumors in postmenopausal women, tumors characterized by certain suspicious ultrasound criteria history of treatment with tamoxifen and genetical predisposal to cancer syndromes. Included patients will undergo preoperatively a Vaginal Ultrasound-Guided Biopsy (VUGB). There will be two histopathological diagnoses for each patient, the first based on the biopsy specimen received preoperatively (Index test) and the second based on the surgical specimen of uterus resected ‘en block’. These diagnoses will be compared in order to assess diagnostic performance of VUGB. Histological criteria used for both diagnoses will be that of Bell et al which were revised by OMS 2014 classification.

403 PHASE 3 TRIAL OF TUMOR TREATING FIELDS CONCOMITANT WITH WEEKLY PACLITAXEL FOR PLATINUM-RESISTANT OVARIAN CANCER: ENGOT-OV50/GOG-329/INNOVATE-3

1Ignace B Vergote, 2Jalid Sehouli, 3Roldano Fossati, 4Robert Coleman, 5Bradley Monk, 6Larry Copeland, 7David O’Malley, 8Leuven Cancer Institute, Leuven, Belgium; Leuven Cancer Institute, Leuven, Belgium; Gynecological Oncology; 9Charité Universitätsmedizin Berlin; Klinik für Gynaikologie; 10Ircs-Istituto DI Ricerche Farmacologiche, Milan; 11MD Anderson Cancer Center University of Texas; 12Ohio State University Comprehensive Cancer Center; 13Ohio State University Comprehensive Cancer Center

10.1136/ijgc-2020-ESGO.198

Introduction/Background Tumor Treating Fields (TTFields) are a non-invasive, antimitotic cancer therapy. The Phase 2 INNOVATE study demonstrated safety of TTFields/weekly paclitaxel in 31 PROC (platinum-resistant ovarian cancer) patients (Vergote Gyn Onc 2018); efficacy: median PFS 8.9 months, 25% partial response, 71% clinical benefit and 61% 1-year survival rate. This phase 3 ENGOT-ov50/GOG-329/INNOVATE-3 study [NCT03940196] investigates TTFields plus weekly paclitaxel in PROC patients.
Results Our primary study hypothesis is that diagnostic performance of VUGB is capable to differentiate fibroma and sarcoma with a sensitivity greater than 90%. Considering as acceptable a sensitivity of 90% (H0) and excellent a sensitivity of 95% (H1), a sample size of 250 patients would be necessary to achieve 80% statistical power with a 5% type-1 statistical error. Taking into account a potential drop-out rate of 10%, there will needed 275 subjects to be included in our study. Primary study endpoint is sensitivity of VUGB anatomico pathological diagnosis. Secondary endpoints include specificity, accuracy Youden’s index, positive and negative predictive values.

Conclusion In case VUGB is demonstrated to be effective and safe to make the differential diagnosis, this should permit preoperatively the stratification of patients to either laparotomy for sarcomas or minimally invasive surgery for benign myomas. Therefore, both unnecessary laparotomies and cancer-spillage by sarcoma morcellations could be avoided at the maximum degree.

Disclosures Authors have nothing to disclose.

Late breaking abstracts

Breast cancer

611 EFFECT OF SENTINEL LYMPH NODE BIOPSY ON UPPER LIMB FUNCTION IN WOMEN WITH EARLY BREAST CANCER: A SYSTEMATIC REVIEW OF CLINICAL TRIALS
Taynara Louisi Pílger, Daniely Franco Francisco, Francisco Jose Candido Dos Reis. Ribeirão Preto Medical School/University of São Paulo, Ribeirão Preto

10.1136/ijgc-2020-ESGO.201

Introduction/Background Axillary surgery is essential in the management of early breast cancer. Conservative procedures like sentinel lymph node biopsy (SLNB) are less invasive than the traditional axillary dissection. However, some extent of ipsilateral upper limb dysfunction might still occur. The aim of this systematic review was to describe the incidence of lymphedema, pain, sensory, and motor disorders after SLNB in women with breast cancer.

Methodology We conducted a systematic review of randomized controlled trials. The search was performed on Pubmed, Embase, CINAHL, and Web of Science. The search was based on the following concepts: breast cancer, sentinel lymph node biopsy, axillary dissection, upper limb complications. The risk of bias was evaluated using the Cochrane Rob 2.0 toll.

Conclusion SLNB is associated with postoperative complications that persist up to at least two years after the surgical procedure. The burden of complications, although lower when compared to axillary dissection, should not be ignored.

Disclosures The authors have no conflict of interest to disclose.

Cervical cancer

576 CLINICAL CHARACTERISTICS, TREATMENT RESPONSE AND PROGNOSIS OF LOCALLY ADVANCED ADENOCARCINOMA OF THE CERVIX, A LOCAL STUDY
Marikou Yu, Jonalyn Bagadiong, Jose R. Reyes Memorial Medical Center; Dr. Jose Fabella Memorial Hospital; Obstetrics and Gynecology Section of Gynecologic Oncology and Trophoblastic Diseases

10.1136/ijgc-2020-ESGO.202

Introduction/Background Treatment of locally advanced cervical carcinoma regardless of histology, either, squamous, adenocarcinoma or adenosquamous carcinoma is the same, concurrent chemoradiotherapy. Nevertheless, studies have different and contradictory results regarding the impact of tumor histology in relation to treatment response. The current study sought to determine the clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma of the cervix in comparison to squamous cell carcinoma.

Methodology Records of the cervical cancer patients from the outpatient department of the Section of Gynecologic Oncology of a tertiary hospital were retrospectively reviewed.